| Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy (NCT04497038) | University of Michigan Rogel Cancer Center | 2021-08-06 |
| Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma (NCT04576572) | Inonu University | 2020-06-15 |
| An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer (NCT04022746) | M.D. Anderson Cancer Center | 2019-06-11 |
| Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer (NCT03211416) | Roswell Park Cancer Institute | 2017-12-07 |
| An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects (NCT02409524) | Mirror Biologics, Inc. | 2016-07-01 |
| A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma (NCT02234986) | CASI pharmaceuticals, Inc. | 2015-10-01 |
| Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (NCT02024087) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2014-08-04 |
| Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma (NCT02418988) | Shenzhen SiBiono GeneTech Co.,Ltd | 2014-07-01 |
| Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer (NCT01666756) | City of Hope Medical Center | 2014-06-11 |
| Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (NCT02042443) | National Cancer Institute (NCI) | 2014-02-01 |
| Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery (NCT02072486) | Roswell Park Cancer Institute | 2013-11-18 |
| Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery (NCT01900002) | M.D. Anderson Cancer Center | 2013-09-13 |
| Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery (NCT01835223) | Roswell Park Cancer Institute | 2013-07-11 |
| A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma (NCT01839604) | AstraZeneca | 2013-05-01 |
| Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma (NCT01777594) | GenSpera, Inc. | 2013-01-01 |
| Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (NCT01488487) | UNC Lineberger Comprehensive Cancer Center | 2011-12-01 |
| Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma (NCT01405573) | National Cancer Institute, Naples | 2011-07-01 |
| Noninvasive Surrogate Marker for Advanced Hepatocellular Carcinoma Response to Concurrent Chemoradiotherapy: MR Perfusion, Contrast Enhanced Ultrasound and Biomarkers (NCT01336452) | Yonsei University | 2011-04-01 |
| MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery (NCT01425879) | National Cancer Institute (NCI) | 2011-04-01 |
| MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy (NCT01239355) | National Cancer Institute (NCI) | 2010-12-01 |
| Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery (NCT01899261) | Montefiore Medical Center | 2010-10-07 |
| MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer (NCT02578602) | University of Southern California | 2010-10-01 |
| Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer (NCT01015833) | National Cancer Institute (NCI) | 2010-02-15 |
| Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (NCT01010126) | National Cancer Institute (NCI) | 2009-09-08 |
| Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer (NCT01008566) | National Cancer Institute (NCI) | 2009-08-01 |
| Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery (NCT00608361) | National Cancer Institute (NCI) | 2008-10-01 |